For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $44.18 in the last session, up 1.52% from day before closing price of $43.52. In other words, the price has increased by $1.52 from its previous closing price. On the day, 0.61 million shares were traded. RNA stock price reached its highest trading level at $44.43 during the session, while it also had its lowest trading level at $42.88.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.
Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 19 ’24 when LEVIN ARTHUR A sold 5,000 shares for $45.19 per share. The transaction valued at 225,946 led to the insider holds 14,830 shares of the business.
Boyce Sarah sold 28,000 shares of RNA for $1,213,822 on Aug 06 ’24. The President and CEO now owns 205,043 shares after completing the transaction at $43.35 per share. On Jul 19 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 5,000 shares for $45.01 each. As a result, the insider received 225,069 and left with 14,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5222915584 and an Enterprise Value of 3560361728. For the stock, the TTM Price-to-Sale (P/S) ratio is 488.15 while its Price-to-Book (P/B) ratio in mrq is 3.95. Its current Enterprise Value per Revenue stands at 335.915 whereas that against EBITDA is -12.595.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.80, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 3.15%, while the 200-Day Moving Average is calculated to be 86.23%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.68M shares per day over the past 3-months and 1691580 shares per day over the past 10 days. A total of 117.12M shares are outstanding, with a floating share count of 106.90M. Insiders hold about 8.73% of the company’s shares, while institutions hold 93.63% stake in the company. Shares short for RNA as of 1722384000 were 12952998 with a Short Ratio of 7.69, compared to 1719532800 on 10834579. Therefore, it implies a Short% of Shares Outstanding of 12952998 and a Short% of Float of 14.850000999999999.
Earnings Estimates
Avidity Biosciences Inc (RNA) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.53 and low estimates of -$0.98.
Analysts are recommending an EPS of between -$2.5 and -$3.51 for the fiscal current year, implying an average EPS of -$2.97. EPS for the following year is -$3.13, with 7.0 analysts recommending between -$2.24 and -$3.9.
